Author Archive: AZBio

AZBioPEERS: Public Policy for the Health Innovation Founder

Posted on by

Public policy decisions can directly influence how health innovations are funded, regulated, reimbursed, adopted, and accessed by patients. This AZBioPEERS video features a discussion hosted by Joan Koerber-Walker, AZBio CEO, with Steve Potts, CEO of Breakthru Medicine, and Tom Eisiminger, Jr., President and CEO of Regenesis Medical, on why policy engagement matters for health innovation entrepreneurs. Panelists will share perspectives on how founders and CEOs can stay informed, build relationships, and make their voices heard on issues that affect company growth, patient access, and Arizona’s broader life science ecosystemContinue reading→

Roche receives FDA clearance for Elecsys® pTau217, advancing Alzheimer’s disease assessment across primary and specialty care

Posted on by
  • First and only FDA-cleared, single-biomarker blood test supporting both rule-in and rule-out assessment of amyloid pathology across primary and specialty care settings
  • The test delivers consistency across clinical settings by using the same validated cutoffs in primary and specialty care
  • Designed for broad implementation across Roche’s installed base of more than 4,500 cobas laboratory instruments in the U.S. supporting access through existing laboratory infrastructureContinue reading→

Your Feedback Wanted on Proposed Changes to Reporting Peer Review Outcomes for Applications

Posted on by

NIH is seeking public comment on proposed changes to the reporting of peer review outcomes for grant applications (NOT-OD-26-088). Comments will be accepted electronically here until October 13, 2026.

These proposed updates are intended to strengthen alignment with the NIH Unified Funding Strategy which prioritizes scientific merit and reinforces the central role of peer review in NIH funding decisions. Under this framework, NIH Institutes, Centers, and Offices (ICOs) should consider peer review information in its entirety.Continue reading→

HHS Seeks Public Input on Federal Vaccine Recommendation Categories and Shared Clinical Decision-Making

Posted on by

WASHINGTON, D.C. — AUGUST 21, 2026 — The U.S. Department of Health and Human Services (HHS) today announced a Request for Information (RFI) seeking public input on the categories used in federal vaccine recommendations and the role of shared clinical decision-making. The RFI advances President Trump’s Executive Order Delivering Gold Standard Childhood Vaccine Recommendations for Americans and supports the Task Force on Safer Childhood Vaccines.Continue reading→

California SB 122: What It Means for Companies

Posted on by

California recently enacted SB 122, which represents a significant expansion of the state’s sales and use tax framework as it applies to digital products, including prewritten computer software delivered electronically and software accessed remotely, including most SaaS and cloud-based arrangements. Under the existing California sales and use tax framework, sales and use tax has generally applied to transactions involving tangible personal property. Persons engaged in the business of rendering services have historically been treated as consumers, not sellers, of tangible personal property used incidentally in rendering those services, and sales and use tax applied to the purchase of such tangible property by such service providers. Because California did not historically include electronically delivered software or SaaS in the definition of digital goods, effective January 1, 2027, the enactment of SB 122 marks a significant development for any company that sells into or buys from California, with meaningful downstream effects across sectors.Continue reading→